Navigation Links
FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
Date:2/17/2011

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with congenital Factor XIII deficiency don't make enough Factor XIII, a substance that circulates in the blood and is important for normal clotting. Without treatment, people with the condition are at risk for life-threatening bleeding.

Congenital Factor XIII deficiency is rare and affects 1 out of every 3 million to 5 million people in the United States. The deficiency may lead to soft tissue bruising, mucosal bleeding and fatal intracranial bleeding. Newborns with Factor XIII deficiency may have umbilical cord bleeding.

"This product helps fill an important need," said Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research.

Corifact received orphan-drug designation by the FDA because it is intended for use in a rare disease or condition. It was approved for marketing under the FDA's accelerated approval regulations that require an on-going study to demonstrate that patients actually receive the clinical benefit predicted by the data obtained so far.

The FDA approved Corifact based on results of a clinical study of 14 people, including children, with congenital Factor XIII deficiency. The most common side effects observed were hypersensitivity reactions (allergy, rash, pruritus, and erythema), chills, fever, arthralgia, headache, elevated thrombin-antithrombin levels, and an increase in liver (hepatic) enzymes.

Corifact is made from the pooled plasma of healthy donors. People receiving Corifact may develop antibodies against Factor XIII that may make the product ineffective. It potentially can cause adverse events from abnormal clotting if doses higher than the labeled dose are given to patients.

Corifact is manufactured by CSL Behring of Marburg, Germany.

For more information:

CBER product approval page:

http://www.fda.gov/BiologicsBloodVaccines/ucm133705.htm

Orphan Products: Hope for People With Rare Diseases

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143563.htm

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First 3-D Mammography Imaging System
2. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
3. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
4. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
5. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
6. FDA Approves Viibryd to Treat Major Depressive Disorder
7. FDA Approves Head Lice Treatment for Children and Adults
8. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
9. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
10. FDA Approves New Dosage Strength for INTELENCE®
11. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/1/2017)... 2017 Michael Penna , President and ... opportunities for growth in his response to the July ... is seeking a buyer for eMDs. Penna,s company, Complete ... solutions Value Added Reseller and national leader in the ... "As the healthcare market continues to dictate consolidation, ...
(Date:8/29/2017)... HAMPTON, Va. , Aug. 29, 2017 ivWatch, LLC, ... of peripheral IV infiltrations, announced it has been awarded an Innovative ... improvement company in the country. ... A continuous monitoring device to aid in the early detection of ... The ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 , ... ... Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. , ... and El Naturalista is a trusted, well-respected brand reliant on the healing properties ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler ... in the U.S. to incorporate magnesium, a critical property for bone health and ...
(Date:9/19/2017)... ... , ... For decades doctors, nurses, and other healthcare providers have been trained ... and calculating their cardiovascular disease (CVD) risk in the next 10 years. , ... today: an estimated 10-year risk prediction! , Imagine if the weatherman says there is ...
(Date:9/19/2017)... York (PRWEB) , ... September 19, 2017 , ... Premiere ... Dr. Andrew Sami, was recently named one of the best dentists in America under ... magazine for dental professionals nationwide. Every fall, the magazine features the best 40 dentists ...
(Date:9/19/2017)... ... 19, 2017 , ... The Davidson Institute for Talent Development ... September 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 ... , “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, ...
Breaking Medicine News(10 mins):